Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial

BACKGROUND: The monthly continuous erythropoietin receptor activator (CERA) utilization maintains stable hemoglobin (Hb) after conversion from weekly epoetin-β (EB); however, how the different pharmacologic properties affect the red blood cell (RBC) size determined by RBC distribution width (RDW) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Uriol-Rivera, Miguel G., Obrador-Mulet, Aina, Jimenez-Mendoza, Sonia, Corral-Baez, Antonio, Perianez-Parraga, Leonor, Garcia-Alvarez, Angel, de la Prada, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734489/
https://www.ncbi.nlm.nih.gov/pubmed/35059087
http://dx.doi.org/10.14740/jh862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734489/
https://www.ncbi.nlm.nih.gov/pubmed/35059087
http://dx.doi.org/10.14740/jh862

Ejemplares similares